Last update: Jan. 7, 2018

ερυθρίνη

Very Low Risk for breastfeeding


Safe. Compatible.
Minimal risk for breastfeeding and infant.

Bioflavonoid type substances.

Flavonoids are phenolic compounds naturally occurring that are abundantly present in plants and seaweed.

We take it from fruits, vegetables, tea and red wine (as a few examples)

Most important types are: anthocyanins, chalcons, flavonols, flavones, flavonoids and tannins. No risk for toxic nor side-effects in humans have been found.

They appear naturally in the breast milk in amounts related to mother's diet.

Attributed anti-oxidant activity and other properties that have not been fully shown yet (Martinez 2016, Morling 2015, Cohen 2012), as amelioration of capillary vessel function which is a reason to be used for treatment of venous insufficiency (varicose veins), hemorrhoids and prevention of arteriosclerosis.

Alternatives

We do not have alternatives for ερυθρίνη since it is relatively safe.

Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

ερυθρίνη is Rutoside in Greek.

Is written in other languages:

ερυθρίνη is also known as

Group

ερυθρίνη belongs to this group or family:

Tradenames

Main tradenames from several countries containing ερυθρίνη in its composition:

List of 6 tradenames

Pharmacokinetics

Variable Value Unit
Molecular weight 665 daltons

References

  1. Martinez-Zapata MJ, Vernooij RW, Uriona Tuma SM, Stein AT, Moreno RM, Vargas E, Capellà D, Bonfill Cosp X. Phlebotonics for venous insufficiency. Cochrane Database Syst Rev. 2016 Abstract
  2. Morling JR, Yeoh SE, Kolbach DN. Rutosides for treatment of post-thrombotic syndrome. Cochrane Database Syst Rev. 2015 Abstract
  3. AESAN. Informe del Comité Científico de la Agencia Española de Seguridad Alimentaria y Nutrición (AESAN) sobre condiciones de uso de determinadas sustancias distintas de vitaminas, minerales y plantas para ser empleadas en complementos alimenticios - 1. Revista del comité científico nº 17. 2012 Full text (in our servers)
  4. Cohen JM, Akl EA, Kahn SR. Pharmacologic and compression therapies for postthrombotic syndrome: a systematic review of randomized controlled trials. Chest. 2012 Abstract
  5. Jaganath IB, Mullen W, Edwards CA, Crozier A. The relative contribution of the small and large intestine to the absorption and metabolism of rutin in man. Free Radic Res. 2006 Abstract
  6. Kienzler JL, Sallin D, Schifflers MH, Ghika A. Pharmacokinetics of mono-3'- and mono-4'-0-(beta-hydroxyethyl)-rutoside derivatives, after single doses of Venoruton powder in healthy volunteers. Eur J Clin Pharmacol. 2002 Abstract
  7. Erlund I, Alfthan G, Mäenpää J, Aro A. Tea and coronary heart disease: the flavonoid quercetin is more bioavailable from rutin in women than in men. Arch Intern Med. 2001 Abstract

Total visits

581

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write to us at elactancia.org@gmail.com

e-lactancia is a resource recommended by IHAN from Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM